Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0699790 (colon cancer)
 28,837 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

PSF3 (partner of Sld five 3) is a member of the tetrameric complex termed GINS, composed of SLD5, PSF1, PSF2, and PSF3, and well-conserved evolutionarily. Previous studies suggested that some GINS complex members are upregulated in cancer, but PSF3 expression in colon carcinoma has not been investigated. Here, we established a mouse anti-PSF3 antibody, and examined PSF3 expression in human colon carcinoma cell lines and colon carcinoma specimens. We found that PSF3 is expressed in the crypt region in normal colonic mucosa and that many PSF3-positive cells co-expressed Ki-67. This suggests that PSF3-positivity of normal mucosa is associated with cell proliferation. Expression of the PSF3 protein was greater in carcinoma compared with the adjacent normal mucosa, and even stronger in high-grade malignancies, suggesting that it may be associated with colon cancer progression. PSF3 gene knock-down in human colon carcinoma cell lines resulted in growth inhibition characterized by delayed S-phase progression. These results suggest that PSF3 is a potential biomarker for diagnosis of progression in colon cancer and could be a new target for cancer therapy.
 ...
PMID:PSF3 marks malignant colon cancer and has a role in cancer cell proliferation. 2005 67

Cancer recurrence has been suggested to be induced by residual cancer-initiating cells (CICs) or cancer stem cells (CSCs) after chemotherapy. Moreover, it is possible that CICs/CSCs acquire more aggressive behavior after therapy as shown by invasion and metastasis. In the cancer microenvironment, CICs/CSCs may localize in a specific area, the so-called stem cell niche, and isolation of this niche is important to elucidate the molecular mechanism of how CICs/CSCs acquire malignancy. We analyzed whether CICs acquire drug resistance after cancer drug treatment in a tumor cell allograft model in which we could identify and isolate living CICs by detecting a higher level of transcriptional activity of the PSF1 gene promoter. In our models using Lewis lung carcinoma (LLC) mouse lung cancer and colon26 mouse colon cancer cell lines, we found that CICs in both tumors acquired drug resistance after cancer drug treatment. Interestingly, response to the anticancer drug was quite different between LLC and colon26 original tumors (ie, the proportion of CICs in LLC tumors increased but in colon26 tumors the proportion decreased). We found that CICs frequently localized near mature blood vessels in which endothelial cells were covered with mural cells and that the incidence of mature blood vessels in LLC tumors was four times higher than in colon26 tumors. These results suggest a relationship between mature blood vessels and CIC drug resistance.
 ...
PMID:Possible role of mural cell-covered mature blood vessels in inducing drug resistance in cancer-initiating cells. 2347 46